MedTrace Logo

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3491

Last updated 2009-03-25

No results posted yet for this study

Summary

The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.

Conditions

  • Acute Coronary Syndromes

Interventions

DRUG

Clopidogrel (SR25990)

plus acetylsalicylic acid (ASA)

DRUG

Placebo

plus acetylsalicylic acid (ASA)

Sponsors & Collaborators

Principal Investigators

  • Eugene Braunwald, MD · Brigham and Women's Hospital, Boston, MA, USA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • France
  • Germany
  • Hungary
  • Ireland
  • Israel
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Puerto Rico
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714961 on ClinicalTrials.gov